270 related articles for article (PubMed ID: 26890877)
1. Effects of dutasteride on lower urinary tract symptoms: a prospective analysis based on changes in testosterone/dihydrotestosterone levels and total prostatic volume reduction.
Shigehara K; Miyagi T; Nakashima T; Izumi K; Kitagawa Y; Mizokami A; Koh E; Shimamura M; Namiki M
Aging Male; 2016 Jun; 19(2):128-33. PubMed ID: 26890877
[TBL] [Abstract][Full Text] [Related]
2. Dutasteride in men receiving testosterone therapy: a randomised, double-blind study.
Kacker R; Harisaran V; Given L; Miner M; Rittmaster R; Morgentaler A
Andrologia; 2015 Mar; 47(2):148-52. PubMed ID: 24499051
[TBL] [Abstract][Full Text] [Related]
3. Effects of dutasteride on serum free-testosterone and clinical significance of testosterone changes.
Enatsu N; Miyake H; Haraguchi T; Chiba K; Fujisawa M
Andrologia; 2016 Dec; 48(10):1195-1201. PubMed ID: 26952737
[TBL] [Abstract][Full Text] [Related]
4. Dutasteride improves bone mineral density in male patients with lower urinary tract symptoms and prostatic enlargement: a preliminary study.
Wada N; Hashizume K; Matsumoto S; Kakizaki H
Aging Male; 2016; 19(1):12-4. PubMed ID: 26225793
[TBL] [Abstract][Full Text] [Related]
5. Influence of dutasteride treatment on serum hormone levels and aging male symptoms in patients with benign prostatic enlargement.
Maeda T; Kikuchi E; Hasegawa M; Homma K; Ando T; Suzuki K; Kaneko G; Mizuno R; Miyajima A; Oya M
Int J Urol; 2018 Jan; 25(1):70-74. PubMed ID: 28975673
[TBL] [Abstract][Full Text] [Related]
6. Early effect of dutasteride added to alpha-1 blocker therapy for patients with lower urinary tract symptoms associated with benign prostatic hyperplasia.
Araki K; Naya Y; Inahara M; Suzuki F; Ota S; Tsuji H; Mikami K; Yanagisawa M; Awa Y; Suzuki H
Int J Urol; 2014 Aug; 21(8):815-9. PubMed ID: 24735081
[TBL] [Abstract][Full Text] [Related]
7. What are the predicting factors for the therapeutic effects of dutasteride in male patients with lower urinary tract symptoms? Investigation using a urodynamic study.
Matsukawa Y; Kato M; Funahashi Y; Majima T; Yamamoto T; Gotoh M
Neurourol Urodyn; 2017 Sep; 36(7):1809-1815. PubMed ID: 28102554
[TBL] [Abstract][Full Text] [Related]
8. The effect of dutasteride on microscopic and macroscopic changes of testosterone replacement treatment on prostate tissue.
Diri MA; Diri B; Yildiz L; Büyükalpelli R
Andrologia; 2018 Dec; 50(10):e13110. PubMed ID: 30024036
[TBL] [Abstract][Full Text] [Related]
9. Effects of Withdrawing α1-Blocker from Combination Therapy with α1-Blocker and 5α-Reductase Inhibitor in Patients with Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia: A Prospective and Comparative Trial Using Urodynamics.
Matsukawa Y; Takai S; Funahashi Y; Majima T; Kato M; Yamamoto T; Gotoh M
J Urol; 2017 Oct; 198(4):905-912. PubMed ID: 28499730
[TBL] [Abstract][Full Text] [Related]
10. Effects of dutasteride on storage and voiding symptoms in male patients with lower urinary tract symptoms as a result of benign prostatic obstruction: the 1-year outcomes from a prospective urodynamic study.
Matsukawa Y; Gotoh M; Kato M; Funahashi Y; Narita M; Mitsui K
Int J Urol; 2014 Aug; 21(8):826-30. PubMed ID: 24661225
[TBL] [Abstract][Full Text] [Related]
11. Effects of dutasteride on lower urinary tract symptoms and general health in men with benign prostatic hypertroplasia and hypogonadism: a prospective study.
Shigehara K; Koh E; Sakamoto J; Yaegashi H; Izumi K; Ueno S; Kitagawa Y; Maeda Y; Kadono Y; Konaka H; Mizokami A; Nakashima T; Namiki M
Aging Male; 2014 Mar; 17(1):51-6. PubMed ID: 24134649
[TBL] [Abstract][Full Text] [Related]
12. Dutasteride reduces prostate size and prostate specific antigen in older hypogonadal men with benign prostatic hyperplasia undergoing testosterone replacement therapy.
Page ST; Hirano L; Gilchriest J; Dighe M; Amory JK; Marck BT; Matsumoto AM
J Urol; 2011 Jul; 186(1):191-7. PubMed ID: 21575967
[TBL] [Abstract][Full Text] [Related]
13. Effect of dutasteride on intraprostatic androgen levels in men with benign prostatic hyperplasia or prostate cancer.
Rittmaster R; Hahn RG; Ray P; Shannon JB; Wurzel R
Urology; 2008 Oct; 72(4):808-12. PubMed ID: 18718641
[TBL] [Abstract][Full Text] [Related]
14. Decreased urinary nerve growth factor reflects prostatic volume reduction and relief of outlet obstruction in patients with benign prostatic enlargement treated with dutasteride.
Wada N; Matsumoto S; Kita M; Hashizume K; Kakizaki H
Int J Urol; 2014 Dec; 21(12):1258-62. PubMed ID: 25039474
[TBL] [Abstract][Full Text] [Related]
15. Finasteride or dutasteride for the pharmacological treatment for male lower urinary tract symptoms due to benign prostatic hyperplasia?
Alcántara-Montero A; Brenes-Bermúdez FJ
Actas Urol Esp; 2016 May; 40(4):268-9. PubMed ID: 26774534
[No Abstract] [Full Text] [Related]
16. Intravesical Prostatic Protrusion as a Predicting Factor for the Adverse Clinical Outcome in Patients With Symptomatic Benign Prostatic Enlargement Treated With Dutasteride.
Yoshida T; Kinoshita H; Yoshida K; Mishima T; Taniguchi H; Yanishi M; Komai Y; Yasuda K; Sugi M; Matsuda T
Urology; 2016 May; 91():154-7. PubMed ID: 26826590
[TBL] [Abstract][Full Text] [Related]
17. The effect of dutasteride on intraprostatic dihydrotestosterone concentrations in men with benign prostatic hyperplasia.
Wurzel R; Ray P; Major-Walker K; Shannon J; Rittmaster R
Prostate Cancer Prostatic Dis; 2007; 10(2):149-54. PubMed ID: 17189955
[TBL] [Abstract][Full Text] [Related]
18. Marked suppression of dihydrotestosterone in men with benign prostatic hyperplasia by dutasteride, a dual 5alpha-reductase inhibitor.
Clark RV; Hermann DJ; Cunningham GR; Wilson TH; Morrill BB; Hobbs S
J Clin Endocrinol Metab; 2004 May; 89(5):2179-84. PubMed ID: 15126539
[TBL] [Abstract][Full Text] [Related]
19. 5α-Reductase inhibitor is less effective in men with small prostate volume and low serum prostatic specific antigen level.
Lin VC; Liao CH; Wang CC; Kuo HC
J Formos Med Assoc; 2015 Sep; 114(9):865-71. PubMed ID: 24064231
[TBL] [Abstract][Full Text] [Related]
20. Influence of baseline variables on changes in International Prostate Symptom Score after combined therapy with dutasteride plus tamsulosin or either monotherapy in patients with benign prostatic hyperplasia and lower urinary tract symptoms: 4-year results of the CombAT study.
Roehrborn CG; Barkin J; Tubaro A; Emberton M; Wilson TH; Brotherton BJ; Castro R
BJU Int; 2014 Apr; 113(4):623-35. PubMed ID: 24127818
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
